Idenix Pharmaceuticals To Present At Three Upcoming Investor Conferences

CAMBRIDGE, Mass., Aug. 29, 2012 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), announced today that Idenix management will participate in a panel discussion at Citigroup's 7 th Annual Biotech Day on September 5, 2012 at 10:45 a.m. ET at the Mandarin Oriental, Boston, and present corporate overviews at the Stifel Nicolaus Healthcare Conference on September 6, 2012 at 3:15 p.m. ET at the Four Seasons, Boston and the Morgan Stanley Global Healthcare Conference on September 10, 2012 at 1:15 p.m. ET at the Grand Hyatt, New York City.

The live and archived webcasts of the company presentations can be accessed under "Events & Presentations" in the Idenix Investor Center at www.idenix.com . Please log in approximately 5-10 minutes before each event to ensure a timely connection. The archived replay will be available on the Idenix website for two weeks following the conferences.

About Idenix

Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases. Idenix's current focus is on the treatment of patients with chronic hepatitis C infection. For further information about Idenix, please refer to http://www.idenix.com .
CONTACT: Idenix Pharmaceuticals Contacts:         Kelly Barry (617) 995-9033 (media)         Daniella Beckman (617) 224-4471 (investors)

If you liked this article you might like

Buffett and Billionaire Investors Look to Oil, Health Care and Spinoffs in 2015

Buffett and Billionaire Investors Look to Oil, Health Care and Spinoffs in 2015

Health Care Stocks: A Year in Review and Predictions for 2015

Health Care Stocks: A Year in Review and Predictions for 2015

'Fast Money' Recap: Next Stop, S&P 2,100?

'Fast Money' Recap: Next Stop, S&P 2,100?

Cramer: Every Which Way But Short

Cramer: Every Which Way But Short

Sarissa Capital: Good Start With Idenix Pharmaceuticals Buyout

Sarissa Capital: Good Start With Idenix Pharmaceuticals Buyout